Penbrook Management’s AbbVie ABBV Stock Holding History

Penbrook Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.12M	Sell	5,170 -60	-1%	-$13.3K	0.85%	35
2025 Q4	$1.2M	Sell	5,230 -43	-0.8%	-$9.79K	0.82%	31
2025 Q3	$1.22M	Sell	5,273 -5,273	-50%	-$1.07M	0.85%	33
2025 Q2	$2.08M	Buy	10,546 +5,273	+100%	+$980K	0.79%	34
2025 Q1	$1.1M	Hold	5,273	–	–	0.84%	29
2024 Q4	$937K	Hold	5,273	–	–	0.64%	43
2024 Q3	$1.04M	Sell	5,273 -100	-2%	-$18.7K	0.68%	35
2024 Q2	$922K	Hold	5,373	–	–	0.56%	38
2024 Q1	$978K	Sell	5,373 -58	-1%	-$10K	0.61%	37
2023 Q4	$842K	Hold	5,431	–	–	0.57%	40
2023 Q3	$810K	Hold	5,431	–	–	0.59%	40
2023 Q2	$732K	Sell	5,431 -300	-5%	-$44K	0.53%	45
2023 Q1	$913K	Hold	5,731	–	–	0.7%	39
2022 Q4	$926K	Sell	5,731 -545	-9%	-$83.6K	0.79%	35
2022 Q3	$842K	Buy	6,276 +26	+0.4%	+$3.73K	0.72%	39
2022 Q2	$957K	Sell	6,250 -1,012	-14%	-$155K	0.75%	37
2022 Q1	$1.18M	Hold	7,262	–	–	0.76%	40
2021 Q4	$983K	Hold	7,262	–	–	0.59%	53
2021 Q3	$783K	Hold	7,262	–	–	0.49%	63
2021 Q2	$818K	Buy	7,262 +164	+2%	+$18.5K	0.49%	62
2021 Q1	$768K	Sell	7,098 -129	-2%	-$13.8K	0.55%	57
2020 Q4	$774K	Buy	7,227 +433	+6%	+$41.6K	0.6%	54
2020 Q3	$595K	Hold	6,794	–	–	0.52%	53
2020 Q2	$667K	Buy	6,794 +2,894	+74%	+$255K	0.66%	45
2020 Q1	$297K	Buy	3,900 +60	+2%	+$5.11K	0.38%	69
2019 Q4	$340K	Hold	3,840	–	–	0.33%	84
2019 Q3	$291K	Hold	3,840	–	–	0.32%	86
2019 Q2	$279K	Hold	3,840	–	–	0.3%	89
2019 Q1	$309K	Hold	3,840	–	–	0.32%	85
2018 Q4	$354K	Hold	3,840	–	–	0.4%	75
2018 Q3	$363K	Hold	3,840	–	–	0.35%	80
2018 Q2	$356K	Hold	3,840	–	–	0.34%	84
2018 Q1	$363K	Hold	3,840	–	–	0.36%	78
2017 Q4	$371K	Buy	+3,840	New	+$362K	0.33%	79
2016 Q3	$242K	Hold	3,840	–	–	0.26%	92
2016 Q2	$238K	Hold	3,840	–	–	0.26%	91
2016 Q1	$219K	Hold	3,840	–	–	0.24%	90
2015 Q4	$227K	Hold	3,840	–	–	0.23%	96
2015 Q3	$209K	Hold	3,840	–	–	0.22%	100
2015 Q2	$258K	Hold	3,840	–	–	0.25%	92
2015 Q1	$225K	Hold	3,840	–	–	0.2%	100
2014 Q4	$251K	Hold	3,840	–	–	0.23%	98
2014 Q3	$222K	Hold	3,840	–	–	0.2%	99
2014 Q2	$217K	Hold	3,840	–	–	0.19%	96
2014 Q1	$203K	Hold	3,840	–	–	0.1%	110
2013 Q4	$203K	Buy	+3,840	New	+$189K	0.2%	91

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Penbrook Management's ABBV Position: Q1 2026 in Review

Penbrook Management reduced its AbbVie (ABBV) stake by 1.1% in Q1 2026, selling an estimated $13.3K and leaving 5,170 shares worth $1.12M. The position accounts for 0.85% of the portfolio, ranked #35.

Penbrook Management first reported a position in ABBV in Q4 2013 and has held it in 46 quarters since. The position peaked at $2.08M in Q2 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Penbrook Management held 5,170 shares of AbbVie worth $1.12M as of Q1 2026.
Penbrook Management sold 60 AbbVie shares in Q1 2026, an estimated $13.3K.
AbbVie made up 0.85% of Penbrook Management's portfolio in Q1 2026, its #35 holding.
Penbrook Management first reported a position in AbbVie in Q4 2013 and has held it in 46 quarters since.
Penbrook Management's AbbVie position peaked at $2.08M in Q2 2025.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Penbrook Management's 13F filing for Q1 2026, filed 21 Apr 2026.